DJIA 17,195.42 221.11 1.30%
NASDAQ 4,566.14 16.91 0.37%
S&P 500 1,994.65 12.35 0.62%
market minute promo

Gilead Sciences (NASDAQ: GILD)

114.22 3.50 (3.16%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

GILD $114.22 3.16%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $110.72
Previous Close $110.72
Daily Range $110.60 - $114.35
52-Week Range $63.50 - $114.35
Market Cap $172.7B
P/E Ratio 18.45
Dividend (Yield) $0.00 (0.0%)
Volume 13,758,107
Average Daily Volume 14,837,121
Current FY EPS $7.26





Gilead Sciences (GILD) Description

Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands about 75% of the U.S. treatment market and more than 50% worldwide. Website:

News & Commentary

5 Things McKesson Corporation's Management Wants You to Know

The Q2 numbers looked great, but here's what McKesson really wants investors to know.

Jim Cramer's 'Mad Money' Recap: Here's Why the Bears Were Dead Wrong

Netflix and Gilead Will See More Gains, Says Thornburg Value Manager

United Therapeutics Sells Off On Good News - Why I Bought That Dip

Is Gilead Sciences a Worthy Investment?

5 Things Bristol-Myers Squibb Co.'s Management Wants You to Know

Bristol-Myers Squibb reported third-quarter earnings last week. Here are five things management wants investors to know.

Update: Gilead Q3 Earnings - Sovaldi Sales Are Down

Top Health Care and Biotech Stocks to Buy That Have Already Posted Earnings

Why You Shouldn't Worry About Gilead Sciences, Inc.

Gilead's Sovaldi sales tumbled 20% in Q3, but that shouldn't concern investors.

Stock Market Today: Stocks Not Spooked by Fed's October Taper

See More GILD News...

GILD's Top Competitors

GILD $114.22 (3.16%)
Current stock: GILD
$0.00 (0.00%)
Current stock:
AMGN $161.58 (1.70%)
Current stock: AMGN
BIIB $321.00 (1.89%)
Current stock: BIIB